Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol

Rheumatology

Volumn 49, Issue 10, 2010, Pages 1900-1910

  Hazes, Johanna M ^a   Taylor, Peter ^b   Strand, Vibeke ^c   Purcaru, Oana ^d   Coteur, Geoffroy ^d   Mease, Philip ^e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UCB PHARMA   (Belgium)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Certolizumab pegol; Daily activities; Fatigue; Household productivity; Pain; Physical function; Rheumatoid arthritis; TNF; Work productivity

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMPLOYMENT STATUS; FAMILY LIFE; FATIGUE; FEMALE; HUMAN; LEISURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PAIN ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SOCIAL LIFE; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EFFICIENCY; FATIGUE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LEISURE ACTIVITIES; MALE; MIDDLE AGED; PAIN; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 77956812620     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq109     Document Type: Article

References (49)

1. Carr A, Hewlett S, Hughes R et al. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003; 30:880-3.
2. Sakalys JA. Illness behavior in rheumatoid arthritis. Arthritis Care Res 1997;10:229-37.
3. Hewlett S, Cockshott Z, Byron M et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697-702.
4. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993;42:93-9.
5. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
6. Plant MJ, O'Sullivan MM, Lewis PA, Camilleri JP, Coles EC, Jessop JD. What factors influence functional ability in patients with rheumatoid arthritis. Do they alter over time? Rheumatology 2005;44:1181-5.
7. Sokka T, Kankainen A, Hannonen P. Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. Arthritis Rheum 2000;43:386-9.
8. Backman CL, Kennedy SM, Chalmers A, Singer J. Participation in paid and unpaid work by adults with rheumatoid arthritis. J Rheumatol 2004;31:47-56.
9. Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med 2006;56:18-27.
10. Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the early RA study (ERAS). Ann Rheum Dis 2002;61:335-40.
11. Allaire SH, Meenan RF, Anderson JJ. The impact of rheumatoid arthritis on the household work performance of women. Arthritis Rheum 1991;34:669-78.
12. Habib G, Artul S, Ratson N, Froom P. Household work disability of Arab housewives with rheumatoid arthritis. Clin Rheumatol 2007;26:759-63.
13. Katz PP, Morris A, Yelin EH. Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis. Ann Rheum Dis 2006;65:763-9.
14. Lacaille D. Arthritis and employment research: where are we? Where do we need to go? J Rheumatol 2005; 32(Suppl. 72):42-45.
15. Sokka T, Kautiainen H, Möttönen T, Hannonen P. Work disability in rheumatoid arthritis 10 year after the diagnosis. J Rheumatol 1999;26:1681-5.
16. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998;25:2108-17.
17. Callahan LF, Bloch DA, Pincus T. Identification of work disability in rheumatoid arthritis: physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variables. J Clin Epidemiol 1992;45:127-38.
18. Mau W, Bornmann M, Weber H, Weidemann HF, Hecker H, Raspe HH. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: results of a tree structured analysis using RECPAM. Br J Rheumatol 1996;35:652-9.
19. Reisine S, McQuillan J, Fifield J. Predictors of work disability in rheumatoid arthritis patients. A five-year followup. Arthritis Rheum 1995;38:1630-7.
20. Verstappen SM, Bijlsma JW, Verkleij H et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488-97.
21. Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987;30: 507-12.
22. Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, von der Schulenburg JM. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology 2008;47:188-93.
23. Puolakka K, Kautiainen H, Mottonen T et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36-41.
24. Puolakka K, Kautiainen H, Mottonen T et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004; 50:55-62.
25. Smolen JS, Han C, van der Heijde D et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22.
26. Reisine ST, Goodenow C, Grady KE. The impact of rheumatoid arthritis on the homemaker. Soc Sci Med 1987;25:89-95.
27. Keystone E, van der Heijde D, Mason D et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum 2008;58:3319-29.
28. Smolen J, Landewé RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. Ann Rheum Dis 2009;68:797-804.
29. Kavanaugh A, Smolen J, Emery P, Purcaru O, Richard L, van Vollenhoven R. Certolizumab pegol with methotrexate improves home and workplace productivity and social activities in patients with active rheumatoid arthritis. Arthritis Care Res 2009;61:1592-600.
30. Strand V, Keininger D, Tahiri-Fitzgerald E. Certolizumab pegol therapy added to methotrexate (MTX) produces clinically meaningful improvements in health-related quality of life and relieves fatigue in patients with rheumatoid arthritis with an incomplete response to MTX: results from RAPID 2 study. Ann Rheum Dis 2007; 66(Suppl. 2):601.
31. Schiff M, Keininger DL, Tahiri-Fitzgerald E. Certolizumab pegol added onto methotrexate improves physical functioning and reduces pain in patient with rheumatoid arthritis who have an incomplete response to methotrexate: data from RAPID 2. Ann Rheum Dis 2007; 66(Suppl. II):187.
32. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005; 64(Suppl. 4):iv2-14.
33. Fries JF, Ramey DR. "Arthritis specific" global health analog scales assess "generic" health related quality-of-life in patients with rheumatoid arthritis. J Rheumatol 1997;24:1697-702.
34. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
35. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
36. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008;14:234-54.
37. Belza B. Self-reported fatigue in rheumatoid arthritis - a pilot study. Arthritis Care Res 1990;3:154-7.
38. Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 2007;57:429-39.
39. Wells G, Li T, Maxwell L, MacLean R, Tugwell P. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 2007;34:280-9.
40. Ware JE, Kosinski M, Gandek B. The SF-36 health survey: a manual and interpretation guide. Lincoln, RI: QualityMetric Incorporated, 2000.
41. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
42. Farrar JT Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
43. Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis specific work productivity survey (WPS-RA). Arthritis Research and Therapy 2009;11:R73.
44. Beaton D, Bombardier C, Escorpizo R et al. Measuring worker productivity: frameworks and measures. J Rheum 2006;36:2100-9.
45. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219-36.
46. Escorpizo R, Bombardier C, Boonen A et al. Worker productivity outcome measures in arthritis. J Rheumatol 2007;34:1372-80.
47. Strand V, Mease P, Burmester GR et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 2009;11:R170.
48. Li T, Gignac M, Wells G, Shen S, Westhovens R. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the abatacept in inadequate responders to methotrexate (AIM) trial. Clin Ther 2008;30:734-48.
49. Revicki DA, Irwin D, Reblando J, Simon GE. The accuracy of self-reported disability days. Med Care 1994;32: 401-4.